4-(Prop-2-enylamino)-1,7-naphthyridine-3-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(Prop-2-enylamino)-1,7-naphthyridine-3-carbonitrile
• 英文别名: 4-(prop-2-enylamino)-1,7-naphthyridine-3-carbonitrile
• 化学式: C₁₂H₁₀N₄
• 分子量: 210.23
• InChiKey: KKFUAGUELXGKKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING -CELL SURVIVAL
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP2911655A1

  公开（公告）日：2015-09-02
• MAP3K8 AS A MARKER FOR SELECTING A PATIENT AFFECTED WITH AN OVARIAN CANCER FOR A TREATMENT WITH A MEK INHIBITOR
  申请人：Institut Curie

  公开号：EP3194973A1

  公开（公告）日：2017-07-26
• TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
  申请人：INSERM (Institut National De La Santé Et De La Recherche Médicale)

  公开号：US20150297573A1

  公开（公告）日：2015-10-22

  The present invention relates to the use of a Tpl2 kinase inhibitor for preventing treating diabetes and promoting β-cell survival and function in a number of applications.
• [EN] TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING &bgr;-CELL SURVIVAL<br/>[FR] INHIBITEURS DE LA KINASE TPL2 POUR PRÉVENIR OU TRAITER LE DIABÈTE ET FAVORISER LA SURVIE DE CELLULES &Bgr;
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2014064215A1

  公开（公告）日：2014-05-01

  The present invention relates to the use of a Tpl2 kinase inhibitor for preventing treating diabetes and promoting β-cell survival and function in a number of applications.
• [EN] MAP3K8 AS A MARKER FOR SELECTING A PATIENT AFFECTED WITH AN OVARIAN CANCER FOR A TREATMENT WITH A MEK INHIBITOR<br/>[FR] MAP3K8 EN TANT QUE MARQUEUR POUR SÉLECTIONNER UNE PATIENTE ATTEINTE D'UN CANCER DE L'OVAIRE POUR UN TRAITEMENT AVEC UN INHIBITEUR DE MEK
  申请人：INST CURIE

  公开号：WO2016041932A1

  公开（公告）日：2016-03-24

  The present invention relates to the use of MAP3K8 protein to predict clinical outcome of a patient affected with a cancer, in particular ovarian cancer, or to select a patient for a treatment comprising one MEK inhibitor. The invention further relates to a method for monitoring a patient affected with a high-MAP3K8 ovarian cancer (i.e. an ovarian cancer with a high expression and/or activity level of MAP3K8) to a treatment comprising at least one MEK inhibitor. The invention also further relates to a MEK inhibitor for use in the treatment of high-MAP3K8 ovarian cancer and kit that can be used in the methods of the invention.